Area of research
Infectious Diseases · Virology
Research interest
Research interests include HIV Research and Treatment, SARS-CoV-2 and COVID-19 Research, Immune Cell Function and Interaction, and COVID-19 Clinical Research Studies.
Identification of a potent V3 glycan site broadly neutralizing antibody targeting an N332gp120 glycan-independent epitope
Autologous neutralizing antibodies and polyfunctional T cells contribute to long-term HIV-1 post-intervention control
Sustained HIV-1 remission after heterozygous CCR5Δ32 stem cell transplantation
Hybrid immunity-based induction of durable pan-endemic-coronavirus immunity in the elderly
Profiling of HIV-1 elite neutralizer cohort reveals a CD4bs bnAb for HIV-1 prevention and therapy
ERBB2 signaling drives immune cell evasion and resistance against immunotherapy in small cell lung cancer
Tertiary Lymphoid Structures in Pancreatic Cancer are Structurally Homologous, Share Gene Expression Patterns and B-cell Clones with Secondary Lymphoid Organs, but Show Increased T-cell Activation
Blocking the angiopoietin-2–dependent integrin β-1 signaling axis abrogates small cell lung cancer invasion and metastasis
Discovery of highly neutralizing human antibodies targeting Pseudomonas aeruginosa
Nucleocapsid-specific T cell responses associate with control of SARS-CoV-2 in the upper airways before seroconversion
Mapping the neutralizing specificity of human anti-HIV serum by deep mutational scanning
Dynamics and durability of HIV-1 neutralization are determined by viral replication
Primary ChAdOx1 vaccination does not reactivate pre-existing, cross-reactive immunity
Short- and long-term T cell and antibody responses following dexamethasone treatment in COVID-19
mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant
SARS-CoV-2 Omicron sublineages exhibit distinct antibody escape patterns
Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial
Analysis of antibodies from HCV elite neutralizers identifies genetic determinants of broad neutralization
Neutralisation sensitivity of the SARS-CoV-2 omicron BA.2.75 sublineage
SARS-CoV-2 mRNA vaccinations fail to elicit humoral and cellular immune responses in patients with multiple sclerosis receiving fingolimod
A naturally arising broad and potent CD4-binding site antibody with low somatic mutation
Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study
CD86+ Antigen-Presenting B Cells Are Increased in Cancer, Localize in Tertiary Lymphoid Structures, and Induce Specific T-cell Responses
Long-term immunogenicity of BNT162b2 vaccination in older people and younger health-care workers
Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers
Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients
Restriction of HIV-1 Escape by a Highly Broad and Potent Neutralizing Antibody
Innovations, challenges, and minimal information for standardization of humanized mice
Rapid SARS-CoV-2 testing in primary material based on a novel multiplex RT-LAMP assay
Hepatitis C reference viruses highlight potent antibody responses and diverse viral functional interactions with neutralising antibodies